Aurora kinase A inhibition

A mega-hit for myelofibrosis therapy?

Richard T. Piszczatowski, Ulrich G. Steidl

Research output: Contribution to journalArticle

Abstract

The positive but limited efficacy of JAK inhibitors has sparked the need for alternative therapeutic targets in the treatment of myelofibrosis. The discovery of novel targets, like Aurora Kinase A, may provide new avenues of single-agent and combinatorial therapy for myelofibrosis and restoration of normal bone marrow function.

Original languageEnglish (US)
Pages (from-to)4868-4870
Number of pages3
JournalClinical Cancer Research
Volume25
Issue number16
DOIs
StatePublished - Jan 1 2019

Fingerprint

Aurora Kinase A
Primary Myelofibrosis
Bone Marrow
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Aurora kinase A inhibition : A mega-hit for myelofibrosis therapy? / Piszczatowski, Richard T.; Steidl, Ulrich G.

In: Clinical Cancer Research, Vol. 25, No. 16, 01.01.2019, p. 4868-4870.

Research output: Contribution to journalArticle

Piszczatowski, Richard T. ; Steidl, Ulrich G. / Aurora kinase A inhibition : A mega-hit for myelofibrosis therapy?. In: Clinical Cancer Research. 2019 ; Vol. 25, No. 16. pp. 4868-4870.
@article{c18bc5f191154b2eb5d08c21c24c1b29,
title = "Aurora kinase A inhibition: A mega-hit for myelofibrosis therapy?",
abstract = "The positive but limited efficacy of JAK inhibitors has sparked the need for alternative therapeutic targets in the treatment of myelofibrosis. The discovery of novel targets, like Aurora Kinase A, may provide new avenues of single-agent and combinatorial therapy for myelofibrosis and restoration of normal bone marrow function.",
author = "Piszczatowski, {Richard T.} and Steidl, {Ulrich G.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1158/1078-0432.CCR-19-1481",
language = "English (US)",
volume = "25",
pages = "4868--4870",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "16",

}

TY - JOUR

T1 - Aurora kinase A inhibition

T2 - A mega-hit for myelofibrosis therapy?

AU - Piszczatowski, Richard T.

AU - Steidl, Ulrich G.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - The positive but limited efficacy of JAK inhibitors has sparked the need for alternative therapeutic targets in the treatment of myelofibrosis. The discovery of novel targets, like Aurora Kinase A, may provide new avenues of single-agent and combinatorial therapy for myelofibrosis and restoration of normal bone marrow function.

AB - The positive but limited efficacy of JAK inhibitors has sparked the need for alternative therapeutic targets in the treatment of myelofibrosis. The discovery of novel targets, like Aurora Kinase A, may provide new avenues of single-agent and combinatorial therapy for myelofibrosis and restoration of normal bone marrow function.

UR - http://www.scopus.com/inward/record.url?scp=85070723611&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070723611&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-19-1481

DO - 10.1158/1078-0432.CCR-19-1481

M3 - Article

VL - 25

SP - 4868

EP - 4870

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 16

ER -